Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer
- PMID: 14984962
- DOI: 10.1016/j.ygyno.2003.11.055
Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer
Abstract
Objectives: This study examines whether expression of COX-2 is associated with clinicopathological features and other molecular markers of ovarian cancer.
Methods: Sixty-four paraffin-embedded tissue specimens were obtained from patients with ovarian cancer who received cytoreductive surgery and combination chemotherapy. Tissue specimens were subjected to immunohistochemical analysis using antibodies to COX-2, p53, and VEGF.
Results: Increased COX-2 expression significantly correlated with histologic type (mucinous 5.6% vs. non-mucinous 65.2%, P<0.001). COX-2 expression was also significantly associated with stage, tumor grade, residual disease status, and presence of ascites. COX-2 expression correlated positively with expression of p53 (P=0.006) and VEGF (P=0.025). Although survival was lower in patients with high COX-2 expression than in those without high COX-2 expression (P<0.001), only tumor grade and stage were independent prognostic indicators. In patients with non-mucinous cancer, COX-2 expression correlated with stage (P<0.001) and presence of ascites (P=0.033).
Conclusions: Our results suggest that expression of COX-2 in ovarian cancers is specific to histologic type of tumor and is associated with poor clinicopathologic prognostic factors. Expression of COX-2 also correlates well with expression of p53 and VEGF.
Similar articles
-
COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates.Oncol Rep. 2004 Feb;11(2):309-13. Oncol Rep. 2004. PMID: 14719060
-
The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.Cancer. 2003 Oct 1;98(7):1423-9. doi: 10.1002/cncr.11650. Cancer. 2003. PMID: 14508829
-
Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.Gynecol Oncol. 2004 Feb;92(2):545-52. doi: 10.1016/j.ygyno.2003.11.016. Gynecol Oncol. 2004. PMID: 14766246
-
[COX-2 expression and ovarian cancer].Akush Ginekol (Sofiia). 2005;44(4):31-3. Akush Ginekol (Sofiia). 2005. PMID: 16028376 Review. Bulgarian.
-
Cox-2 expression in ovarian malignancies: a review of the clinical aspects.Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):129-32. doi: 10.1016/j.ejogrb.2009.05.030. Epub 2009 Jun 25. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19559517 Review.
Cited by
-
Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.J Clin Pathol. 2007 Mar;60(3):307-10. doi: 10.1136/jcp.2005.035717. Epub 2006 May 12. J Clin Pathol. 2007. PMID: 16698954 Free PMC article.
-
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Cancers (Basel). 2010 May 26;2(2):913-54. doi: 10.3390/cancers2020913. Cancers (Basel). 2010. PMID: 24281100 Free PMC article.
-
Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer.Front Pharmacol. 2025 Apr 30;16:1520771. doi: 10.3389/fphar.2025.1520771. eCollection 2025. Front Pharmacol. 2025. PMID: 40371356 Free PMC article.
-
Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer.Genes Nutr. 2011 May;6(2):109-15. doi: 10.1007/s12263-011-0209-y. Epub 2011 Feb 4. Genes Nutr. 2011. PMID: 21484164 Free PMC article.
-
COX-2 expression in ovarian cancer: an updated meta-analysis.Oncotarget. 2017 Oct 4;8(50):88152-88162. doi: 10.18632/oncotarget.21538. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous